Monoclonal antibody drug discovery focus
|Telephone:||+44 (0)1223 833 301|
|Address:||Meditrina (B260), Babraham Research Campus, Babraham|
|Membership type:||Corporate 51+ (£1,000+VAT pa)|
Using world-class embryonic stem cell and recombineering technologies, Kymab has developed a proprietary human antibody discovery platform, Kymouse™. The platform is designed to have a superior repertoire of B-cell mediated immune responses to current in vivo systems. We are using the Kymouse™ platform to discover and develop potent and selective therapies.
As a “platform to product” biopharmaceutical company, our strategy is to use our proprietary Kymouse ™ for the in-house development of a product portfolio and to partner with others to maximise its application in the development of novel therapeutics.
Kymab Group Limited, a leading monoclonal antibody biopharmaceutical group, announced today that it has received a $9m grant from the Bill & Melinda Gates Foundation to accelerate the development of novel vaccines and therapeutics for infectious diseases, including HIV.
9 January 2017Read in full
Kymab's new therapeutic antibody for autoimmune diseases, KY1005, shows potential for improvement in post-transplant survival in an animal model of Graft-versus-Host Disease.
6 December 2016Read in full
Kymab Limited, a leading human monoclonal antibody biopharmaceutical company based at the Babraham Research Campus, and EpimAb Biotherapeutics, Inc., an emerging Chinese biopharmaceutical company specialising in bispecific antibodies, today announced a cross-licensing and development agreement to develop bispecific therapeutic antibodies against multiple targets.
11 October 2016Read in full